Prognostic features and treatment outcome in patients with nasopharymgeal carcinoma: An experience of 20 years

Citation
V. Tombolini et al., Prognostic features and treatment outcome in patients with nasopharymgeal carcinoma: An experience of 20 years, ANTICANC R, 21(2B), 2001, pp. 1413-1418
Citations number
26
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTICANCER RESEARCH
ISSN journal
02507005 → ACNP
Volume
21
Issue
2B
Year of publication
2001
Pages
1413 - 1418
Database
ISI
SICI code
0250-7005(200103/04)21:2B<1413:PFATOI>2.0.ZU;2-1
Abstract
Background. The best treatment of Nasopharyngeal Calcinoma (NPC) is still a n open question. The purpose of this retrospective study was to determine r isk factors that affect lacoregional control and treatment outcome of NPC p atients after radiotherapy, with or without chemotherapy. Methods. Between January 1976 and December 1996, 66 consecutive patients (stage I=0; stage I I=13; stage III=32; stageIV=21) were given definitive radiotherapy at a sin gle Institution. Concurrent or adjuvant chemotherapy was also given to 14 o f them (21%). Multivariate analysis was performed to evaluate age, T stage, N stage, radiotherapy dose, histology, chemotherapy bone of skull erosions or cranial nerve palsies and base of skull involvement as prognostic facto rs of locoregional control and overall survival. Results. By the end of Jan uary 2000 after a median follow-up of 66 months and a minimal follow-up of 36 months, the event-free overall survival rate of 5 years was 48% and the overall survival 54%. Risk factor analysis revealed that radiotherapy dose, age and stage were the most importantfactors for overall survival of these patients. The 5 year overall survival was 89% for stage II and 49% for sta ge III-IV (p = 0.004), 62% for dose higher than 60 Gy and 20% for dose belo w 60 Gy (p = 0.007), 62% for age below 65 years and 36% for age higher than 65 years (p = 0.027). The concurrent or adjuvant chemotherapy did not have prognostic significance. Conclusions. We confirm the need to determine the risk factors in patients with NPC. The choice of treatment, whether radiot herapy alone, at dose > 60 Gy, or radiotherapy plus chemotherapy, should be made after identification of patients with high risk disease, suitable for the combined modality.